How much evidence isn't in evidence-based guidelines? (English)
- New search for: Johnson, M. J.
- New search for: Currow, D. C.
- New search for: Johnson, M. J.
- New search for: Currow, D. C.
In:
ANNALS OF ONCOLOGY
;
27
, 1
;
205-205
;
2016
-
ISSN:
- Article (Journal) / Print
-
Title:How much evidence isn't in evidence-based guidelines?
-
Contributors:Johnson, M. J. ( author ) / Currow, D. C. ( author )
-
Published in:ANNALS OF ONCOLOGY ; 27, 1 ; 205-205
-
Publisher:
- New search for: OXFORD UNIVERSITY PRESS
-
Publication date:2016-01-01
-
Size:1 pages
-
ISSN:
-
Type of media:Article (Journal)
-
Type of material:Print
-
Language:English
- New search for: 616.992
- Further information on Dewey Decimal Classification
-
Classification:
DDC: 616.992 -
Source:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.
Table of contents – Volume 27, Issue 1
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 1
-
thanks to referees 2015| 2016
- 6
-
The influential and inspirational Gianni Bonadonna's life commitment to evidence-based cancer medicineCurigliano, G. / Valagussa, P. / Veronesi, U. / Gianni, L. et al. | 2016
- 8
-
Annals of oncology in 2015: the year in reviewSoria, J. C. et al. | 2016
- 10
-
Statistical controversies in clinical research: assessing pathologic complete response as a trial-level surrogate end point for early-stage breast cancerKorn, E. L. / Sachs, M. C. / McShane, L. M. et al. | 2016
- 16
-
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up†Colombo, N. / Creutzberg, C. / Amant, F. / Bosse, T. / González-Martín, A. / Ledermann, J. / Marth, C. / Nout, R. / Querleu, D. / Mirza, M. R. et al. | 2016
- 42
-
Prognostic impact and implications of extracapsular lymph node involvement in colorectal cancer: a systematic review with meta-analysisVeronese, N. / Nottegar, A. / Pea, A. / Solmi, M. / Stubbs, B. / Capelli, P. / Sergi, G. / Manzato, E. / Fassan, M. / Wood, L. D. et al. | 2016
- 49
-
Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysisRaggi, D. / Miceli, R. / Sonpavde, G. / Giannatempo, P. / Mariani, L. / Galsky, M. D. / Bellmunt, J. / Necchi, A. et al. | 2016
- 62
-
Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromesKomrokji, R. S. / List, A. F. et al. | 2016
- 68
-
Risk factors for neuroendocrine neoplasms: a systematic review and meta-analysisLeoncini, E. / Carioli, G. / La Vecchia, C. / Boccia, S. / Rindi, G. et al. | 2016
- 81
-
Fruits, vegetables and lung cancer risk: a systematic review and meta-analysisVieira, A. R. / Abar, L. / Vingeliene, S. / Chan, D. S. / Aune, D. / Navarro-Rosenblatt, D. / Stevens, C. / Greenwood, D. / Norat, T. et al. | 2016
- 96
-
Early market access of cancer drugs in the EUMartinalbo, J. / Bowen, D. / Camarero, J. / Chapelin, M. / Démolis, P. / Foggi, P. / Jonsson, B. / Llinares, J. / Moreau, A. / O'Connor, D. et al. | 2016
- 106
-
Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer†O'Shaughnessy, J. / Campone, M. / Brain, E. / Neven, P. / Hayes, D. / Bondarenko, I. / Griffin, T. W. / Martin, J. / De Porre, P. / Kheoh, T. et al. | 2016
- 114
-
Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study†Tewari, K. S. / Java, J. J. / Eskander, R. N. / Monk, B. J. / Burger, R. A. et al. | 2016
- 121
-
Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001–02)†Aparicio, T. / Lavau-Denes, S. / Phelip, J. M. / Maillard, E. / Jouve, J. L. / Gargot, D. / Gasmi, M. / Locher, C. / Adhoute, X. / Michel, P. et al. | 2016
- 127
-
Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancerKuboki, Y. / Yamashita, S. / Niwa, T. / Ushijima, T. / Nagatsuma, A. / Kuwata, T. / Yoshino, T. / Doi, T. / Ochiai, A. / Ohtsu, A. et al. | 2016
- 134
-
Prognostic factors for progression-free and overall survival in advanced biliary tract cancerBridgewater, J. / Lopes, A. / Wasan, H. / Malka, D. / Jensen, L. / Okusaka, T. / Knox, J. / Wagner, D. / Cunningham, D. / Shannon, J. et al. | 2016
- 140
-
A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trialHagman, H. / Frödin, J. E. / Berglund, . / Sundberg, J. / Vestermark, L. W. / Albertsson, M. / Fernebro, E. / Johnsson, A. et al. | 2016
- 147
-
Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategiesIlie, M. / Long-Mira, E. / Bence, C. / Butori, C. / Lassalle, S. / Bouhlel, L. / Fazzalari, L. / Zahaf, K. / Lalvée, S. / Washetine, K. et al. | 2016
- 154
-
A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers†Li, B. T. / Drilon, A. / Johnson, M. L. / Hsu, M. / Sima, C. S. / McGinn, C. / Sugita, H. / Kris, M. G. / Azzoli, C. G. et al. | 2016
- 159
-
Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registryWagstaff, J. / Jones, R. / Hawkins, R. / Porfiri, E. / Pickering, L. / Bahl, A. / Brown, J. / Buchan, S. et al. | 2016
- 165
-
Comprehensive serum cytokine analysis identifies IL-1RA and soluble IL-2Rα as predictors of event-free survival in T-cell lymphomaGupta, M. / Stenson, M. / O'Byrne, M. / Maurer, M. J. / Habermann, T. / Cerhan, J. R. / Weiner, G. W. / Witzig, T. E. et al. | 2016
- 172
-
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial†Weinstein, C. / Jordan, K. / Green, S. A. / Camacho, E. / Khanani, S. / Beckford-Brathwaite, E. / Vallejos, W. / Liang, L. W. / Noga, S. J. / Rapoport, B. L. et al. | 2016
- 178
-
Metabolic phenotyping of human blood plasma: a powerful tool to discriminate between cancer types?Louis, E. / Adriaensens, P. / Guedens, W. / Vanhove, K. / Vandeurzen, K. / Darquennes, K. / Vansteenkiste, J. / Dooms, C. / de Jonge, E. / Thomeer, M. et al. | 2016
- 185
-
Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study)Takeuchi, K. / Togashi, Y. / Kamihara, Y. / Fukuyama, T. / Yoshioka, H. / Inoue, A. / Katsuki, H. / Kiura, K. / Nakagawa, K. / Seto, T. et al. | 2016
- 192
-
The reporting of adverse events in oncology phase III trials: a comparison of the current status versus the expectations of the EORTC membersMaillet, D. / Blay, J. Y. / You, B. / Rachdi, A. / Gan, H. K. / Péron, J. et al. | 2016
- 199
-
A clinical case of invasive lobular breast carcinoma with ERBB2 and CDH1 mutations presenting a dramatic response to anti-HER2-directed therapyGrellety, T. / Soubeyran, I. / Robert, J. / Bonnefoi, H. / Italiano, A. et al. | 2016
- 200
-
Two cases of EGFR mutation-positive lung adenocarcinoma that transformed into squamous cell carcinoma: successful treatment of one case with rociletinibHaratani, K. / Hayashi, H. / Watanabe, S. / Kaneda, H. / Yoshida, T. / Takeda, M. / Shimizu, T. / Nakagawa, K. et al. | 2016
- 202
-
More on sunitinib 2 weeks on/1 week off schedule: the Rainbow analysisBasso, U. / Maruzzo, M. et al. | 2016
- 202
-
A rational approach for salvage of testicular cancer patientsSelle, F. / Soares, D. G. / Lotz, J. P. et al. | 2016
- 203
-
Reply to the letter to the editor ‘The ESMO Magnitude of Clinical Benefit Scaling Tool: from theory to practice’ by Hartmann and the letter ‘Comment on ESMO Magnitude of Clinical Benefit Scale’ by Muhonen et al.Cherny, N. I. / Sullivan, R. / Dafni, U. / Kerst, J. M. / Sobrero, A. / Zielinski, C. / de Vries, E. G. / Piccart, M. J. et al. | 2016
- 205
-
How much evidence isn't in evidence-based guidelines?Johnson, M. J. / Currow, D. C. et al. | 2016
- 206
-
PD-L1 copy number gain in nonsmall-cell lung cancer defines a new subset of patients for anti PD-L1 therapyGoldmann, T. / Kugler, C. / Reinmuth, N. / Vollmer, E. / Reck, M. et al. | 2016
- 206
-
Enzalutamide and sleep apnea: an emerging central nervous system side-effect?Labrize, F. / Cany, L. / Massard, C. / Loriot, Y. / Sargos, P. / Gross-Goupil, M. / Roubaud, G. et al. | 2016
- 208
-
Vitamin D and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Case–Control ConsortiumWaterhouse, M. / Risch, H. A. / Bosetti, C. / Anderson, K. E. / Petersen, G. M. / Bamlet, W. R. / Cotterchio, M. / Cleary, S. P. / Ibiebele, T. I. / La Vecchia, C. et al. | 2016
- 209
-
Planning and reporting of quality-of-life outcomes in cancer trialsSchandelmaier, S. / Conen, K. / von Elm, E. / You, J. J. / Blümle, A. / Tomonaga, Y. / Saccilotto, R. / Amstutz, A. / Bengough, T. / Meerpohl, J. J. et al. | 2016